Nutriband Clarifies Fentanyl Designation Impact, Advances Abuse-Deterrent Patch Development

Nutriband Inc. responded to the Trump Administration's Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction, clarifying that this designation should not be conflated with FDA-approved prescription fentanyl therapies. The company emphasized that transdermal fentanyl patches are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. This distinction is crucial as regulatory discussions evolve around balancing legitimate medical needs with substance abuse prevention efforts.

The company highlighted ongoing concerns around transdermal fentanyl patch abuse and accidental pediatric exposure. In response, Nutriband is partnering with Kindeva to develop AVERSA™ FENTANYL, which combines Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. This collaboration aims to deter abuse and reduce accidental exposure while maintaining access for patients who need prescription fentanyl products. According to the company's website at https://www.nutriband.com, Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.

Nutriband stated that AVERSA™ FENTANYL could be the first abuse-deterrent opioid patch on the market. The company projects potential peak annual U.S. sales of $80 million to $200 million, with an initial focus on the U.S. market and a stated goal of broader availability in major global medical markets. The development represents a significant step in addressing the opioid crisis while preserving legitimate medical use of fentanyl for pain management. The AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

These developments come at a time when balancing pain management needs with substance abuse prevention remains a significant public health challenge, making technological solutions like abuse-deterrent formulations increasingly important in medical practice and regulatory discussions. The full press release containing this information can be viewed at https://ibn.fm/AHvva. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. This technology represents a critical innovation in pharmaceutical safety measures that could influence both clinical practice and regulatory frameworks surrounding controlled substance medications.